Summary
Three inborn errors of galactose metabolism are known, one for each step in the Leloir pathway of galactose conversion to glucose. The first, galactokinase deficiency, is discovered either through newborn screening for hypergalactosemia, or by the chance finding of reducing substance in urine, or by selective urine screening for galactose in infants or older persons examined for nuclear cataracts. In the undiagnosed newborn drinking milk, cataracts develop insidiously within a few weeks as the only clinical manifestation. Galactose-galactitol-glucose diabetes is the only chemical sign. Diagnosis is made by enzyme assay on blood cells or fibroblasts. For treatment, milk and milk products are eliminated from the diet. In transferase deficiency or galactosemia, the second step in the Leloir pathway is blocked. In most developed countries, this defect is discovered through newborn screening, and the more serious clinical symptoms are avoided by prompt treatment. Infants who remain undiagnosed develop symptoms and signs of liver and kidney failure and succumb to sepsis. Survivors develop cataracts and mental impairment. Diagnosis is suggested by the presence of reducing substance in the urine of the fed newborn, and it is made by enzyme assay on blood cells, a liver biopsy specimen, or fibroblasts. Lifelong exclusion of all galactose from the diet is stipulated, but difficult to achieve. Partial transferase deficiency is more frequent than the complete defect. It is treated by a less-than-complete removal of dietary galactose, usually restricted to the first few months of life. The third defect of the Leloir pathway, epimerase deficiency, occurs in both a benign mild form and a severe and crippling form. Both are discovered through newborn screening, using methods sensitive to galactose-1-phosphate and are diagnosed by enzyme assay on blood cells or fibroblasts. Infants with the mild form do not seem to require treatment. The two documented severe cases showed clinical features reminiscent of untreated galactosemia; their dietary treatment proved difficult and unsatisfactory.
“Whenever you consider a galactose disorder, stop milk feeding first and only then seek a diagnosis.”
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gitzelmann R, Hansen RG (1980) Galactose metabolism, hereditary defects and their clinical significance. In: Burman D, Holton JB, Pennock CA (eds) Inherited disorders of carbohydrate metabolism. MTP, Lancaster, pp 61–101
Segal S (1989) Disorders of galactose metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 453–480
Gitzelmann R, Steinmann B (1984) Galactosemia: how does long-term treatment change the outcome? Enzyme 32: 37–46
Gitzelmann R (1980) Newborn screening for inherited disorders of galactose metabolism. In: Bickel H, Guthrie R, Hammersen G (eds) Neonatal screening for inborn errors of metabolism. Springer, Berlin Heidelberg New York, pp 67–79
Beutler E, Paniker NV, Trinidad F (1971) The assay of red cell galactokinase. Biochem Med 5: 325–332
Mayes JS, Guthrie R (1968) Detection of heterozygotes for galactokinase deficiency in a human population. Biochem Genet 2: 219–230
Gitzelmann R (1967) Hereditary galactokinase deficiency, a newly recognized cause of juvenile cataracts. Pediatr Res 1: 14–23
Gitzelmann R (1987) This week’s citation classic. Curr Contents Life Sci 30: 14
Levy HL, Sepe SJ, Walton DS, Shih VE, Hammersen G, Houghton S, Beutler E (1978) Galactose-1-phosphate uridyl transferase deficiency due to Duarte-galactosemia combined variation: clinical and biochemical studies. J Pediatr 92: 390–393
Wharton CH, Berry HK, Bofinger MK (1978) Galactose-l-phosphate accumulation by a Duarte-transferase deficiency double heterozygote. Clin Genet 13: 171–175
Schwarz HP, Zuppinger KA, Zimmerman A, Dauwalder H, Scherz R, Bier DM (1982) Galactose intolerance in individuals with double heterozygosity for Duarte variant and galactosemia. J Pediatr 100: 704–709
Schwarz HP, Schaefer T, Bachmann C (1985) Galactose and galactitol in the urine of children with compound heterozygosity for Duarte variant and classical galactosemia (GtD/gt) after an oral galactose load. Clin Chem 31: 420–422
Jakobs C, Kleijer WJ, Bakker HD, van Gennip AH, Przyrembel H, Niermeijer MF (1988) Dietary restriction of maternal lactose intake does not prevent accumulation of galactitol in the amniotic fluid of fetuses affected with galactosaemia. Prenat Diagn 8: 641–645
Gitzelmann R, Steinmann B (1973) Uridine diphosphate galactose 4-epimerase deficiency II. Clinical follow-up, biochemical studies and family investigation. HeIv Paediatr Acta 28: 497–510
Gitzelmann R (1969) Formation of galactose-1-phosphate from uridine diphosphate galactose in erythrocytes from patients with galactosemia. Pediatr Res 3: 279–286
Gitzelmann R, Hansen RG (1974) Galactose biogenesis and disposal in galactosemics. Biochim Biophys Acta 372: 374–378
Gitzelmann R, Hansen RG, Steinmann B (1975) Biogenesis of galactose, a possible mechanism of self-intoxication in galactosemia. In: Hommes FA, Van den Berg CJ (eds) Normal and pathological development of energy metabolism. Academic, London, pp 25–37
Donnell GN, Koch R, Fishier K, Ng WG (1980) Clinical aspects of galactosaemia. In: Burman D, Holton JB, Pennock CA (eds) Inherited disorders of carbohydrate metabolism. MTP, Lancaster, pp 103–115
Kaufman FR, Donnell GN, Roe TF, Kogut MD (1986) Gonadal function in patients with galactosaemia. J Inherited Metab Dis 9: 140–146
Donnell GN, Bergren WR (1975) The galactosaemias. In: Raine DN (ed) The treatment of inherited metabolic disease. MTP, Lancaster, pp 91–114
Brandt NJ (1980) How long should galactosaemia be treated? In: Burman D, Holton JB, Pennock CA (eds) Inherited disorders of carbohydrate metabolism. MTP, Lancaster, pp 117–124
Koch R, Acosta P, Ragsdale N, Donnell GN (1963) Nutrition in the treatment of galactosemia. J Am Diet Assoc 43: 216–222
Koch R, Acosta P, Donnell G, Lieberman E (1965) Nutritional therapy of galactosemia. Management success depends on rigid exclusion of all galactose-containing foods. Clin Pediatr 4: 571–576
Clothier CM, Davidson DC (1983) Galactosaemia workshop. Hum Nutr Appl Nutr 37A: 483–490
Gitzelmann R, Auricchio S (1965) The handling of soya alpha-galactosides by a normal and a galactosemic child. Pediatrics 36: 231–235
Steffen C (1975) Enzymatische Bestimmungsmethoden zur Erfassung der Gärungsvorgänge in der milchwirtschaftlichen Technologie. Lebensm Wiss Technol 8: 1–6
Kaufman FR, Ng WG, Xu YK, Guidici T, Kaleita TA, Donnell GN (1989) Treatment of patients (PTS) with classical galactosemia ( G) with oral uridine. Pediatr Res 25: 142A
Rogers S, Bovee BW, Segal S (1989) Effect of uridine on hepatic galactose-1-phosphate uridyltransferase. Enzyme 42: 53–60
Sardharwalla IB, Komrower GM, Schwarz V (1980) Pregnancy in classical galactosaemia. In: Burman D, Holton JB, Pennock CA (eds) Inherited disorders of carbohydrate metabolism. MTP, Lancaster, pp 125–132
Gitzelmann R (1969) Estimation of galactose-1-phosphate in erythrocytes: a rapid and simple enzymatic method. Clin Chim Acta 26: 313–316
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gitzelmann, R. (1990). Disorders of Galactose Metabolism. In: Fernandes, J., Saudubray, JM., Tada, K. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-02613-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-662-02613-7_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-02615-1
Online ISBN: 978-3-662-02613-7
eBook Packages: Springer Book Archive